,18 These characterizations not only match the observed benefit NKG2A+ biases provide patients with cancer but also align with clinical and biological characterizations of NKG2A+ CD8+ T cells and biases we observed in infection and autoimmunity contexts. Here, CD8A is linked to cancer.